OPHTHALMOLOGY CLINIC BUSINESS PLAN
I. Executive Summary
Company Description
LuminEye Ophthalmic Center (name derived from "lumen" meaning light and "eye") is a premier specialized medical practice in Houston, Texas, operating in the ophthalmology sector. We provide advanced clinical and surgical eye care on a fee-for-service model, staffed by board-certified ophthalmologists and sub-specialists in retina and glaucoma. Our state-of-the-art clinical and surgical center is designed for efficiency and superior patient outcomes. One-liner: launching January 2026 to deliver high-quality, high-volume specialized eye care.
We offer comprehensive services—complex retinal surgery, glaucoma surgery and management, medical retina care, and perioperative clinic services—distinguished by integrated surgical suites, sub-specialist teams, and a workflow built for throughput and outcomes. Main activities include surgical scheduling, chronic disease clinics, referral coordination, and post-op management. Target market: adults with retinal and glaucoma disease, seniors, and referring ophthalmologists/optometrists in Greater Houston. Short-term goal: open and stabilize full operations by January 2026; long-term goal: become the regional leader in specialized eye care.
Problem
Millions of Americans live with vision impairment and blindness from conditions such as cataracts, glaucoma, and diabetic retinopathy; in the Houston metropolitan area, an aging population faces a measurable lack of efficient, technologically advanced eye care.
Patients encounter long surgical wait times that can cause permanent sight degradation, and chronic diseases require high-frequency monitoring that current facilities struggle to deliver. The market lacks a patient-centric scheduling and capacity model that maximizes practitioner availability for timely, personalized care.
Necessity: a state-of-the-art, fee-for-service clinical and surgical center launching January 2026 that reduces wait times, increases monitoring frequency, expands specialist availability, and targets $1,334,000 EBITDA by year-end 2026.
Solution
We close a critical gap in metropolitan eye care by delivering comprehensive diagnostics and complex surgical services under one roof, reducing wait times and preventing avoidable vision loss for patients with cataracts, glaucoma, and diabetic retinopathy. Our model combines immediate access to leading specialists with modern imaging, AI-assisted screening, and streamlined practice workflows to shorten diagnosis-to-treatment time and improve outcomes.
Core services include OCT diagnostics, AI-assisted retinal and glaucoma screening, intravitreal and glaucoma procedures, premium cataract and refractive surgery with advanced lenses and laser platforms, and advanced practice management software; clinical KPIs track measurable vision outcomes and patient-reported quality-of-life improvements. Financial target: USD 3,504,000 in EBITDA by 2027.
Mission Statement
Our mission is to preserve and restore the gift of sight by delivering the most advanced, efficient, and compassionate ophthalmological care, grounded in clinical integrity and superior surgical outcomes. We commit to using cutting-edge technology and proven expertise to improve quality of life for every patient, with a patient-first approach and operational excellence. We ensure access to necessary treatments and continuous improvement so individuals can maintain vision for a lifetime.
Key Success Factors
Critical drivers of success are operational efficiency, pricing, capital investment, payor and referral relationships, and experienced management.
-
90% practitioner capacity utilization by 2030 achieved through efficient scheduling.
-
20-month payback driven by high-volume surgeries at an average price of $3,500.
-
$2,285,000 capital investment in advanced surgical and diagnostic equipment.
-
Strong insurance and physician referral relationships ensuring steady patient flow.
-
Experienced management delivering 45.36% ROE via disciplined financial and operational oversight.
Financial Summary
The clinic is forecast to produce strong EBITDA growth from launch through 2028, with rapid breakeven and a moderate IRR.
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
$3,610,000 |
$9,487,000 |
$19,205,000 |
Projected EBITDA |
$1,334,000 |
$3,504,000 |
$7,093,000 |
Expected ROI |
9% |
9% |
9% |
Financial requirements: total launch CapEx $2,285,000; returns: IRR 9%, payback ~20 months, breakeven Jan-26.
Overall, the financial outlook shows rapid EBITDA scale and a positive return profile.
Funding Requirements
We require $3,117,000 to fund the 2026 commercial launch, covering capital expenditures, build-out, equipment, and working capital to reach breakeven in month one and deliver a 9% IRR by year five.
Categories |
Amount, USD |
Product Development |
|
Marketing |
|
Operations |
|
Staffing (initial hires) |
|
Medical Technology & Equipment |
$1,785,000 |
Facility Build-out |
$500,000 |
Other CapEx |
|
Working capital |
$832,000 |
Total funding required |
$3,117,000 |